Cumberland Pharmaceuticals
CPIX
26 hedge funds and large institutions have $17M invested in Cumberland Pharmaceuticals in 2020 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 5 increasing their positions, 5 reducing their positions, and 6 closing their positions.
1.43% more ownership
Funds ownership: 29.38% → 30.81% (+1.4%)
0% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 5
4% less funds holding
Funds holding: 27 → 26 (-1)
17% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 6
26% less capital invested
Capital invested by funds: $23M → $17M (-$5.99M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BAM
Berkshire Asset Management
Wilkes Barre,
Pennsylvania
|
+$736K |
| 2 |
AI
Ariel Investments
Chicago,
Illinois
|
+$331K |
| 3 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
+$51.8K |
| 4 |
Victory Capital Management
San Antonio,
Texas
|
+$13.2K |
| 5 |
Renaissance Technologies
New York
|
+$10.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
B
Bailard
Foster City,
California
|
-$61K |
| 2 |
Dimensional Fund Advisors
Austin,
Texas
|
-$34.5K |
| 3 |
Acadian Asset Management
Boston,
Massachusetts
|
-$24.8K |
| 4 |
ACM
Anfield Capital Management
Irvine,
California
|
-$23K |
| 5 |
BlackRock
New York
|
-$17.7K |
CPIX Hedge Fund Activity: Q1 2020 in Review
26 of the 4,538 institutional investors tracked by Wall St. Rank reported a position in Cumberland Pharmaceuticals (CPIX) for Q1 2020, worth a combined $17M — down 26% from $23M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of CPIX and 5 opened new positions — a net loss of 1 holder — while 5 trimmed existing stakes and 5 added.
The largest buyer was Berkshire Asset Management, opening a new position worth an estimated $736K. The largest seller was Bailard, exiting entirely with an estimated $61K sold.
- 26 institutional investors held Cumberland Pharmaceuticals (CPIX) as of Q1 2020, down from 27 in Q4 2019.
- Funds reported $17M of Cumberland Pharmaceuticals stock for Q1 2020, down 26% quarter-over-quarter.
- 5 funds opened new Cumberland Pharmaceuticals positions in Q1 2020 and 6 closed out, a net change of -1 holder.
- The largest Cumberland Pharmaceuticals buyer in Q1 2020 was Berkshire Asset Management, an estimated $736K added.
- The largest Cumberland Pharmaceuticals seller in Q1 2020 was Bailard, an estimated $61K sold.
Based on aggregated 13F filings for Q1 2020.